Clinical Utility of Central and Peripheral Airway Nitric Oxide in Aging Patients with Stable and Acute Exacerbated Chronic Obstructive Pulmonary Disease

Xiaodong Fan; Nian Zhao; Zhen Yu; Haoda Yu; Bo Yin; Lifei Zou; Yinying Zhao; Xiufen Qian; Xiaoyan Sai; Chu Qin; Congli Fu; Caixia Hu; Tingting Di; Yue Yang; Yan Wu; Tao Bian

doi:10.2147/IJGM.S284688

Clinical Utility of Central and Peripheral Airway Nitric Oxide in Aging Patients with Stable and Acute Exacerbated Chronic Obstructive Pulmonary Disease

Int J Gen Med. 2021 Feb 23:14:571-580. doi: 10.2147/IJGM.S284688. eCollection 2021.

Authors

Xiaodong Fan^#¹, Nian Zhao^#^{2

3}, Zhen Yu¹, Haoda Yu¹, Bo Yin¹, Lifei Zou¹, Yinying Zhao¹, Xiufen Qian¹, Xiaoyan Sai¹, Chu Qin¹, Congli Fu¹, Caixia Hu¹, Tingting Di¹, Yue Yang¹, Yan Wu¹, Tao Bian¹

Affiliations

¹ Departments of Pulmonary and Critical Care Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China.
² Departments of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunshan, Kunshan, Jiangsu, 215300, People's Republic of China.
³ The first medical college of Nanjing Medical University, NanJing, Jiangsu, 211166, People's Republic of China.

^# Contributed equally.

Abstract

Purpose: Exhaled nitric oxide has been used as a marker of airway inflammation. The NO concentration in the central and peripheral airway/alveolar can be measured by a slow and fast exhalation flow rate to evaluate inflammation in different divisions within the respiratory tract. We hypothesized that FeNO₂₀₀ (exhaled NO at a flow rate of 200mL/s) could be used as an evaluation tool for peripheral airway/alveolar inflammation and corticosteroid therapy in chronic obstructive pulmonary disease (COPD) patients.

Methods: We recruited 171 subjects into the study: 73 healthy controls, 59 stable COPD patients, and 39 acute exacerbations of COPD (AECOPD) patients. Exhaled nitric oxide (FeNO₅₀ (exhaled NO at a flow rate of 50mL/s)), FeNO₂₀₀ and CaNO (peripheral concentration of NO/alveolar NO) and clinical variables including pulmonary function, COPD Assessment Test (CAT), C-reactive protein concentration (CRP) and circulating eosinophil count were measured among the recruited participants. FeNO_50, FeNO₂₀₀ and CaNO were repeatedly evaluated in 39 AECOPD patients after corticosteroid treatment.

Results: FeNO₂₀₀ was significantly higher in stable COPD and AECOPD patients than in healthy controls. Nevertheless, CaNO could not differentiate COPD from healthy controls. No correlation was found between circulating eosinophil counts or FEV1 and exhaled nitric oxide (FeNO_50, FeNO₂₀₀, CaNO) in COPD patients. For AECOPD patients, 64% of patients had eosinophil counts >100 cells/µL; 59% of patients had FeNO₂₀₀ >10 ppb; only 31% of patients had FeNO₅₀ > 25 ppb. Among AECOPD patients, the high FeNO₅₀ and FeNO₂₀₀ groups' levels were significantly lower than their baseline levels, and significant improvements in CAT were seen in the two groups after corticosteroid treatment. These implied a good corticosteroid response in AECOPD patients with FeNO₂₀₀>10ppb.

Conclusion: FeNO₂₀₀ is a straightforward and feasible method to evaluate the peripheral NO concentration in COPD. FeNO200 can be a type 2 inflammation biomarker and a useful tool for predicting corticosteroid therapy in COPD.

Keywords: biomarker; chronic obstruction pulmonary disease; corticosteroid; exhaled nitric oxide.